Jazz projects $4.25B-$4.50B 2026 revenue while advancing rare disease and oncology launches
Source: SeekingAlpha
2026-02-25 00:58:23 ET
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
- 44th Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Jazz Pharmaceuticals Q4 2025 Earnings Preview
- Jazz boasts of first-line Ziihera data in gastroesophageal cancers
Read the full article on Seeking Alpha
For further details see:
Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches
Jazz Pharmaceuticals plc
NASDAQ: JAZZ
JAZZ Trading
-2.85% G/L:
$179.96 Last:
456,039 Volume:
$179.685 Open:
JAZZ Latest News
February 24, 2026 04:05:00 pm
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
February 10, 2026 04:15:00 pm
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
JAZZ Stock Data
$10,064,526,163
58,152,216
1.22%
231
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 4
